Glytec Secures $36M to Advance AI-Powered Diabetes Care Platform

Glytec, a healthcare technology company specializing in AI-powered diabetes management solutions, has secured $36 million in growth investment led by Savitr Capital and Hayfin Capital Management. The funding arrives at a critical time as healthcare systems confront mounting pressure to improve inpatient glycemic control amid new Centers for Medicare & Medicaid Services quality measures that will hold hospitals accountable for performance outcomes.

The investment will fuel continued expansion of Glytec's technology platform, with particular focus on its flagship Glucommander® Software-as-a-Service solution. The capital will also accelerate the development of innovative technologies while supporting research and development initiatives, platform scaling efforts, and recruitment of top-tier talent across the organization.

The healthcare industry faces a growing diabetes crisis that places enormous strain on hospital systems nationwide. Over one-third of all hospitalized patients require insulin therapy, yet effective management of elevated blood glucose levels remains a persistent clinical challenge. Each year, more than two million patients experience adverse hospital events leading to hypoglycemia, generating healthcare costs exceeding $8 billion while contributing to extended lengths of stay and increased readmission rates.

Despite these significant risks and financial implications, nearly one-third of hospitals operate without glucose management metrics, and 59 percent lack automated methods for tracking hyperglycemia and hypoglycemia rates. This gap in systematic monitoring and management creates substantial opportunities for improved patient safety and cost reduction through technology-enabled solutions.

Glucommander® is a cloud-based software solution for inpatient glycemic management, holding the distinction as the first FDA-cleared cloud-based insulin management platform. The system currently serves over 400 hospitals nationwide, helping healthcare providers improve patient safety outcomes, reduce operational costs, and increase revenue generation through more effective diabetes care protocols.

"This investment is a pivotal moment for Glytec, validating our vision of a future where deep data-driven insights empower clinicians to deliver highly individualized and proactive care for diabetes and metabolic conditions," said Patrick Cua, CEO of Glytec. "Savitr Capital and Hayfin Capital share our belief in the transformative power of technology to improve patient outcomes and alleviate the burden of complex chronic diseases."

The funding positions Glytec to capitalize on increasing regulatory requirements and growing recognition of technology's role in addressing the diabetes management challenge facing healthcare systems across the United States.

Click here for the original news story.